T-VEC Immunotherapy Shows Promising Early Activity in Melanoma

Bryant FurlowJun 7, 2018The genetically engineered oncolytic herpes simplex virus produced promising clinical responses in stage IIIB –IVM1a melanoma.

Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news